Opinion|Videos|February 11, 2025
Patient Perspectives on Managing Side Effects from Amivantamab
Panelists discuss the side effects Melinda has experienced with her current treatment and the strategies she has found most helpful in managing them, while Julia outlines her typical monitoring and follow-up procedures for patients receiving amivantamab, including the frequency of follow-up visits, labs, imaging, and the symptoms or labs that are most concerning during follow-up.
Advertisement
Video content above is prompted by the following:
- Dr. Spira asks Melinda: What side effects have you experienced with your current treatment?
- What strategies have you found to be most helpful in managing these side effects?
- Dr. Spira asks Julia: Briefly outline your typical monitoring and follow-up procedures for patients receiving amivantamab at your institution.
- How often do you see your patients for follow up?
- What labs and imaging are typically ordered and at what frequency?
- During follow up, what symptoms or labs are most concerning to you?
Advertisement
Related to this article
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.
Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
3
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5